$EGRX
EAGLE PHARMACEUTICALS, INC.

2021 Q4 Form 10-Q Financial Statement

#000082787121000029 Filed on November 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2021 Q2
Revenue $42.32M $39.85M $48.12M
YoY Change -15.22% -20.18% 14.75%
Cost Of Revenue $12.31M $5.486M $7.907M
YoY Change -1.84% -37.13% -23.33%
Gross Profit $30.01M $34.37M $40.22M
YoY Change -19.71% -16.59% 27.17%
Gross Profit Margin 70.91% 86.23% 83.57%
Selling, General & Admin $20.33M $18.48M $16.64M
YoY Change 11.74% 4.44% -7.37%
% of Gross Profit 67.73% 53.78% 41.37%
Research & Development $3.787M $23.29M $9.911M
YoY Change -59.71% 382.37% 38.91%
% of Gross Profit 12.62% 67.77% 24.64%
Depreciation & Amortization $1.067M $197.0K $188.0K
YoY Change 21.25% 0.51% -10.05%
% of Gross Profit 3.56% 0.57% 0.47%
Operating Expenses $24.11M $41.77M $26.55M
YoY Change -12.57% 85.44% 5.79%
Operating Profit $5.899M -$10.18M $10.82M
YoY Change -39.81% -166.01% 191.72%
Interest Expense -$4.530M $396.0K $422.0K
YoY Change 1061.54% -19.02% -46.31%
% of Operating Profit -76.79% 3.9%
Other Income/Expense, Net -$145.0K -$2.483M -$5.272M
YoY Change -107.29% -61.75% -416.83%
Pretax Income $1.224M -$12.66M $5.548M
YoY Change -89.25% -241.85% 3.26%
Income Tax $7.420M -$7.038M $1.936M
% Of Pretax Income 606.21% 34.9%
Net Earnings -$6.196M -$5.622M $3.612M
YoY Change -176.87% -179.64% -1510.94%
Net Earnings / Revenue -14.64% -14.11% 7.51%
Basic Earnings Per Share -$0.43 $0.28
Diluted Earnings Per Share -$480.5K -$0.43 $0.27
COMMON SHARES
Basic Shares Outstanding 12.91M shares 13.08M shares 13.11M shares
Diluted Shares Outstanding 13.08M shares 13.26M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $103.0M $104.3M $108.7M
YoY Change -0.18% 16.27% 0.48%
Cash & Equivalents $97.66M $99.74M $108.7M
Short-Term Investments $5.312M $4.551M
Other Short-Term Assets $3.159M $2.428M $4.458M
YoY Change 96.82% -33.86% 256.64%
Inventory $21.91M $9.315M $8.294M
Prepaid Expenses
Receivables $41.15M $45.34M $52.66M
Other Receivables $0.00 $1.746M $0.00
Total Short-Term Assets $172.6M $171.7M $175.5M
YoY Change 3.94% 4.82% 4.2%
LONG-TERM ASSETS
Property, Plant & Equipment $1.636M $1.775M $1.967M
YoY Change -21.23% -16.39% -7.13%
Goodwill $39.74M $39.74M $39.74M
YoY Change 0.0% 0.0% 0.0%
Intangibles $10.67M $10.80M $11.51M
YoY Change -17.39% -20.5% -19.26%
Long-Term Investments
YoY Change
Other Assets $10.28M $14.54M $21.46M
YoY Change -40.27% 7.09% 22.1%
Total Long-Term Assets $81.13M $84.57M $88.74M
YoY Change -6.89% 0.24% 0.53%
TOTAL ASSETS
Total Short-Term Assets $172.6M $171.7M $175.5M
Total Long-Term Assets $81.13M $84.57M $88.74M
Total Assets $253.7M $256.3M $264.2M
YoY Change 0.21% 3.26% 2.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $16.43M $12.72M $11.14M
YoY Change 162.14% -2.69% -18.76%
Accrued Expenses $32.34M $27.71M $25.53M
YoY Change 35.78% 13.37% 29.07%
Deferred Revenue $3.046M $4.339M
YoY Change -57.23% -24.85%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $25.61M $8.000M $8.000M
YoY Change 220.09% 0.0% 14.29%
Total Short-Term Liabilities $74.38M $48.43M $44.66M
YoY Change 95.29% 6.41% 10.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $19.49M $21.37M
YoY Change -100.0% -27.86% -26.05%
Other Long-Term Liabilities $2.903M $3.048M $3.360M
YoY Change -26.67% 7.17% -0.03%
Total Long-Term Liabilities $2.903M $22.54M $24.73M
YoY Change -90.02% -24.53% -23.34%
TOTAL LIABILITIES
Total Short-Term Liabilities $74.38M $48.43M $44.66M
Total Long-Term Liabilities $2.903M $22.54M $24.73M
Total Liabilities $77.28M $70.97M $69.40M
YoY Change 15.03% -5.85% -4.61%
SHAREHOLDERS EQUITY
Retained Earnings $75.86M $82.06M $87.68M
YoY Change -10.21% 7.36% 26.39%
Common Stock $17.00K $17.00K $17.00K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $225.1M $216.5M $208.2M
YoY Change 10.4% 8.31% 17.72%
Treasury Stock Shares 4.112M shares 3.942M shares 3.783M shares
Shareholders Equity $176.5M $185.3M $194.8M
YoY Change
Total Liabilities & Shareholders Equity $253.7M $256.3M $264.2M
YoY Change 0.21% 3.26% 2.93%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2021 Q2
OPERATING ACTIVITIES
Net Income -$6.196M -$5.622M $3.612M
YoY Change -176.87% -179.64% -1510.94%
Depreciation, Depletion And Amortization $1.067M $197.0K $188.0K
YoY Change 21.25% 0.51% -10.05%
Cash From Operating Activities $8.081M $1.067M $8.591M
YoY Change -59.1% -81.05% -58.99%
INVESTING ACTIVITIES
Capital Expenditures -$49.00K -$5.000K $111.0K
YoY Change -71.18% -97.5% 23.33%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities -$49.00K -$5.000K $111.0K
YoY Change -71.18% -97.5% 23.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -10.11M -10.04M -5.220M
YoY Change 65.26% -58.09% -95.46%
NET CHANGE
Cash From Operating Activities 8.081M 1.067M 8.591M
Cash From Investing Activities -49.00K -5.000K 111.0K
Cash From Financing Activities -10.11M -10.04M -5.220M
Net Change In Cash -2.082M -8.976M 3.482M
YoY Change -115.46% -51.53% -103.71%
FREE CASH FLOW
Cash From Operating Activities $8.081M $1.067M $8.591M
Capital Expenditures -$49.00K -$5.000K $111.0K
Free Cash Flow $8.130M $1.072M $8.480M
YoY Change -59.21% -81.61% -59.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity File Number
EntityFileNumber
001-36306
dei Entity Central Index Key
EntityCentralIndexKey
0000827871
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2021Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2021Q3 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
Eagle Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8179278
dei Entity Address Address Line1
EntityAddressAddressLine1
50 Tice Boulevard
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 315
dei Entity Address City Or Town
EntityAddressCityOrTown
Woodcliff Lake
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07677
dei City Area Code
CityAreaCode
(201)
dei Local Phone Number
LocalPhoneNumber
326-5300
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
EGRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12913879 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99741000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103155000 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
45335000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
50678000 USD
CY2021Q3 us-gaap Liabilities
Liabilities
70968000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
9315000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
8075000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
17303000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4157000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
171694000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
166065000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1775000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2077000 USD
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10799000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12917000 USD
CY2021Q3 us-gaap Goodwill
Goodwill
39743000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
39743000 USD
CY2021Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
17713000 USD
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
15180000 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14537000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
17208000 USD
CY2021Q3 us-gaap Assets
Assets
256261000 USD
CY2020Q4 us-gaap Assets
Assets
253190000 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
12717000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6268000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27714000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23817000 USD
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
8000000 USD
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
8000000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
48431000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
38085000 USD
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3048000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3959000 USD
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
19489000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
25135000 USD
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
256261000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
67179000 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1500000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1500000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16886123 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16739203 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
17000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
17000 USD
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
320566000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
305403000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-882000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
82058000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
84489000 USD
CY2021Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
3941541 shares
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
3682176 shares
CY2021Q3 us-gaap Treasury Stock Value
TreasuryStockValue
216466000 USD
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
203898000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
185293000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
186011000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
253190000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
39853000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
49928000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
129226000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
137886000 USD
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5486000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8726000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
21835000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
23804000 USD
CY2021Q3 us-gaap Royalty Expense
RoyaltyExpense
2773000 USD
CY2020Q3 us-gaap Royalty Expense
RoyaltyExpense
3260000 USD
us-gaap Royalty Expense
RoyaltyExpense
8036000 USD
us-gaap Royalty Expense
RoyaltyExpense
9120000 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23289000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4828000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47488000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21390000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
34511000 USD
us-gaap Costs And Expenses
CostsAndExpenses
132356000 USD
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
18482000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17697000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
54997000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
60411000 USD
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
50030000 USD
us-gaap Costs And Expenses
CostsAndExpenses
114725000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10177000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
15417000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-3130000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
23161000 USD
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
197000 USD
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
46000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
395000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
542000 USD
CY2021Q3 us-gaap Interest Expense
InterestExpense
396000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
489000 USD
us-gaap Interest Expense
InterestExpense
1240000 USD
us-gaap Interest Expense
InterestExpense
2164000 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2284000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6049000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1797000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10249000 USD
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2483000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6492000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2642000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11871000 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12660000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
8925000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5772000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
11290000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7038000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1866000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3341000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7358000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-5622000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
7059000 USD
us-gaap Net Income Loss
NetIncomeLoss
-2431000 USD
us-gaap Net Income Loss
NetIncomeLoss
3932000 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.29
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.28
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13077298 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13531372 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13103203 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13620981 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13077298 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13786803 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13103203 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13917800 shares
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-5622000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
7059000 USD
us-gaap Net Income Loss
NetIncomeLoss
-2431000 USD
us-gaap Net Income Loss
NetIncomeLoss
3932000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
22000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-882000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
22000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-882000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5600000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
7059000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3313000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3932000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
194847000 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4084000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
233000 USD
CY2021Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
8271000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
22000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-5622000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
185293000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
186011000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14873000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1841000 USD
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-1551000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
12568000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-882000 USD
us-gaap Net Income Loss
NetIncomeLoss
-2431000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
185293000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
183964000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4722000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
42000 USD
CY2020Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
23000000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
7059000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
172787000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
179174000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18435000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
555000 USD
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1310000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
27999000 USD
us-gaap Net Income Loss
NetIncomeLoss
3932000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
172787000 USD
us-gaap Net Income Loss
NetIncomeLoss
-2431000 USD
us-gaap Net Income Loss
NetIncomeLoss
3932000 USD
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-2533000 USD
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-1671000 USD
us-gaap Depreciation
Depreciation
575000 USD
us-gaap Depreciation
Depreciation
656000 USD
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
768000 USD
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
980000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2118000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1999000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-1900000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-7700000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
14873000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
18435000 USD
us-gaap Debt Securities Available For Sale Change In Present Value Expense Reversal
DebtSecuritiesAvailableForSaleChangeInPresentValueExpenseReversal
150000 USD
us-gaap Debt Securities Available For Sale Change In Present Value Expense Reversal
DebtSecuritiesAvailableForSaleChangeInPresentValueExpenseReversal
0 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
354000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
301000 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
254000 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-2549000 USD
egrx Accretion Income
AccretionIncome
102000 USD
egrx Accretion Income
AccretionIncome
0 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5343000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4195000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1240000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
20000 USD
egrx Increase Decreasein Prepaid Expenseand Other Current Assets Total
IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal
8821000 USD
egrx Increase Decreasein Prepaid Expenseand Other Current Assets Total
IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal
2774000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6449000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7606000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3897000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3916000 USD
us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
908000 USD
us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
1845000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
20138000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
29737000 USD
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
0 USD
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
17500000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
274000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
577000 USD
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
5000000 USD
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5274000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18077000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1841000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
555000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1551000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1310000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
110000000 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
110000000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
6000000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3000000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
12568000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
27999000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-18278000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-31754000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3414000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20094000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
103155000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
109775000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
99741000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89681000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
6303000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
3036000 USD
us-gaap Interest Paid Net
InterestPaidNet
917000 USD
us-gaap Interest Paid Net
InterestPaidNet
1878000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
842000 USD
us-gaap Basis Of Accounting
BasisOfAccounting
Basis of Presentation and Other Company Information <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting quarterly information. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. The condensed consolidated balance sheet at December 31, 2020 was derived from audited financial statements, but certain information and footnote disclosures normally included in our annual consolidated financial statements have been condensed or omitted. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made. Results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results for the year ending December 31, 2021 or any period thereafter. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on March 5, 2021. </span></div><div style="margin-bottom:6pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an integrated pharmaceutical company focused on finding ways to help medicines do more for patients. We and our collaborators have the capabilities to take a molecule from preclinical research through regulatory approval and into the marketplace, including development, manufacturing and commercialization. Our business model applies our scientific expertise, proprietary research-based insights and marketplace proficiency to identify challenging-to-treat diseases of the central nervous system or metabolic critical care therapeutic areas as well as in oncology. By focusing on patients' unmet needs, we strive to provide healthcare professionals with urgently needed treatment solutions that are designed to improve patient care and outcomes and create near- and long-term value for our stakeholders, including patients and healthcare providers and our employees, marketing partners, collaborators and investors. Our science-based business model has a proven track record with U.S. Food and Drug Administration ("FDA") approval and commercial launches of three products: Ryanodex® (dantrolene sodium) ("Ryanodex"), bendamustine ready-to-dilute ("RTD") 500ml solution ("Belrapzo"), and rapidly infused bendamustine RTD ("Bendeka"). We market our products through marketing partners and/or our internal direct sales force. We market Ryanodex and Belrapzo, and Teva Pharmaceutical Industries Ltd. ("Teva") markets Bendeka through its subsidiary Cephalon, Inc. SymBio Pharmaceuticals Limited, or SymBio, marke</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ts Treakisym, a RTD product, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Japan. Reflecting further expansion of our oncology portfolio, in February 2020, we received final FDA approval for Pemfexy, a branded alternative to Alimta for metastatic non-squamous non-small cell lung cancer and malignant pleural mesothelioma. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With several pipeline projects underway and the potential for up to five product launches over the next several years, we believe we have many growth opportunities ahead. We believe that each of our pipeline projects currently has the potential to enter the market as a first-in-class, first-to-file, first-to-market or best-in-class product. In particular, we are applying our expertise to conduct novel research regarding the potential for Ryanodex to address conditions inclu</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ding Alzheimer’s disease, traumatic brain injury/concussion, nerve agent exposure and acute radiation syndrome. In ad</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dition, our clinical development program includes a strategic partnership with Tyme Technologies, Inc., or Tyme, for Tyme’s product candidate for the treatment of patients with pancreatic or other advanced cancers, SM-88, as well as investigations of compounds such as EA-114 (our fulvestrant product candidate) for patients with HR-positive advanced breast cancer. Other products in development include Vasopressin, ou</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r first-to-file Abbreviated New Drug Application, or ANDA, that references Endo International plc’s Vasostrict indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines; and EA-111, a new chemical entity and next-generation ryanodine receptor antagonist, in an intramuscular formulation that that would allow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for easier and more rapid administration in emergency situations (military and civilian).</span></div>
egrx Number Of Products Launched
NumberOfProductsLaunched
3 product
CY2021Q3 egrx Number Of Potential Future Product Launches
NumberOfPotentialFutureProductLaunches
5 product
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. Our critical accounting policies are those that are both most important to our financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. We anticipate that the COVID-19 pandemic will continue to disrupt our supply chain and marketing and sales efforts for certain of our products, including Bendeka, although it is not currently expected that any disruption would be significant. As of the date of issuance of these financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, assumptions and judgments or revise the carrying value of our assets or liabilities. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates, and any such differences may be material to our financial statements.</span></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform with the current year presentation, including for amounts related to accounts receivable, net and prepaid expenses and other current assets. None of the amounts pertaining to the reclassifications were significant.</span></div>
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13531372 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13103203 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13620981 shares
CY2021Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
95255000 USD
CY2021Q3 us-gaap Receivables Fair Value Disclosure
ReceivablesFairValueDisclosure
3795000 USD
CY2021Q3 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Asset
EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset
530000 USD
CY2021Q3 us-gaap Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
10300000 USD
CY2021Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
109880000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
79682000 USD
CY2020Q4 us-gaap Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
12200000 USD
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
91882000 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2020Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2021Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2021Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
500000 USD
CY2020Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
300000 USD
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
1300000 USD
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
2200000 USD
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2446657 shares
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3362057 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2901595 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3130198 shares
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5622000 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
7059000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2431000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
3932000 USD
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13077298 shares
CY2020Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
255431 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
296819 shares
CY2021Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
13077298 shares
CY2020Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
13786803 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
13103203 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
13917800 shares
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.29
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.28
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7542000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7268000 USD
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5767000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5191000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1775000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2077000 USD
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
197000 USD
CY2020Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
196000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
575000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
656000 USD
CY2021Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
6006000 USD
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3515000 USD
CY2021Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1309000 USD
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
2589000 USD
CY2021Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2000000 USD
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1971000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
9315000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
8075000 USD
CY2021Q3 us-gaap Prepaid Taxes
PrepaidTaxes
5898000 USD
CY2020Q4 us-gaap Prepaid Taxes
PrepaidTaxes
0 USD
CY2021Q3 egrx Prepaid Fda User Fee
PrepaidFDAUserFee
1478000 USD
CY2020Q4 egrx Prepaid Fda User Fee
PrepaidFDAUserFee
1262000 USD
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
468000 USD
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
191000 USD
CY2021Q3 egrx Advances To Commercial Manufacturers
AdvancesToCommercialManufacturers
734000 USD
CY2020Q4 egrx Advances To Commercial Manufacturers
AdvancesToCommercialManufacturers
660000 USD
CY2021Q3 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
1746000 USD
CY2020Q4 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
439000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
4551000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1199000 USD
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
2428000 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1605000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
17303000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4157000 USD
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3046000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4966000 USD
CY2021Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
4879000 USD
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
5996000 USD
CY2021Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
5255000 USD
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
4686000 USD
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2552000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2370000 USD
CY2021Q3 egrx Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
8528000 USD
CY2020Q4 egrx Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
2724000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1123000 USD
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2255000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1952000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
27714000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23817000 USD
CY2021Q3 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P3Y3M18D
CY2021Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
us-gaap Operating Lease Payments
OperatingLeasePayments
1040000 USD
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
1323000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
855000 USD
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M18D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1199000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3048000 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4247000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
23100000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
12301000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
10799000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
23100000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
10183000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
12917000 USD
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
706000 USD
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
667000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2118000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
185615 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3096161 shares
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1999000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
504000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1369000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1570000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1898000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1520000 USD
CY2021Q3 egrx Finite Lived Intangible Assets Expected Amortization After Year Four
FiniteLivedIntangibleAssetsExpectedAmortizationAfterYearFour
3938000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
10799000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
662700 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
41951 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3531295 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3331890 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
109000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
100477 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
308815 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3031598 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0051
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0112
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0037
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0165
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5607
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5498
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y8M4D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y10D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4084000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4722000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14873000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18435000 USD
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4084000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4722000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14873000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18435000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4680000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
351000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1423000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1455000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1038000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
413000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
0 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
0 USD
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
28000000 USD
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
2000000 USD
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
26000000 USD
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0 USD
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
0 USD
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
0 USD
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
0 USD
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
0 USD
CY2021Q3 us-gaap Purchase Obligation
PurchaseObligation
53176000 USD
CY2021Q3 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
53176000 USD
CY2021Q3 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
0 USD
CY2021Q3 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
0 USD
CY2021Q3 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
0 USD
CY2021Q3 us-gaap Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
0 USD
CY2021Q3 us-gaap Purchase Obligation Due In Fifth Year
PurchaseObligationDueInFifthYear
0 USD
CY2021Q3 us-gaap Purchase Obligation Due After Fifth Year
PurchaseObligationDueAfterFifthYear
0 USD
CY2021Q3 us-gaap Contractual Obligation
ContractualObligation
85856000 USD
CY2021Q3 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
55527000 USD
CY2021Q3 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
27423000 USD
CY2021Q3 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
1455000 USD
CY2021Q3 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
1038000 USD
CY2021Q3 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
413000 USD
CY2021Q3 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
0 USD
CY2021Q3 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
0 USD
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
325000 USD
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
276000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
976000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
910000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4700000 USD
CY2021Q3 us-gaap Purchase Obligation
PurchaseObligation
53200000 USD
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
8000000 USD
CY2021Q3 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
500000 USD
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
2000000 USD
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
26000000 USD
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
28000000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7038000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1866000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3341000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7358000 USD
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.56
CY2020Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.21
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.58
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.65
egrx Number Of Tax Jurisdictions Currently Auditing The Company
NumberOfTaxJurisdictionsCurrentlyAuditingTheCompany
3 jurisdiction
CY2021Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD

Files In Submission

Name View Source Status
0000827871-21-000029-index-headers.html Edgar Link pending
0000827871-21-000029-index.html Edgar Link pending
0000827871-21-000029.txt Edgar Link pending
0000827871-21-000029-xbrl.zip Edgar Link pending
egrx-20210930.htm Edgar Link pending
egrx-20210930.xsd Edgar Link pending
egrx-20210930_cal.xml Edgar Link unprocessable
egrx-20210930_def.xml Edgar Link unprocessable
egrx-20210930_htm.xml Edgar Link completed
egrx-20210930_lab.xml Edgar Link unprocessable
egrx-20210930_pre.xml Edgar Link unprocessable
ex102eagle-aoplicenseagree.htm Edgar Link pending
exhibit101redacted.htm Edgar Link pending
exhibit311q32021.htm Edgar Link pending
exhibit312q32021.htm Edgar Link pending
exhibit321q32021.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending